A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC-9)
PI: Dr. Chen
Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion
